US President Donald Trump on Monday, 19 May announced a sweeping expansion of his administration's prescription drug discount platform TrumpRX.gov, adding more than 600 generic medicines in partnership with pharmacy and pharmaceutical companies — nearly a seven-fold increase in the number of drugs available on the government-backed site. The announcement was made at a healthcare affordability event at the White House.

What the Expansion Covers

The newly added medicines span treatments for diabetes, obesity, fertility, and insulin, among others. The platform is designed to help consumers compare drug prices before purchase and surface lower-cost generic alternatives that many Americans reportedly do not know exist. According to Trump, the site has already logged more than 10 million visits since its launch earlier this year and has reportedly saved consumers over $400 million.

Key Voices at the White House Event

Billionaire entrepreneur Mark Cuban, co-founder of Cost Plus Drugs, appeared alongside Trump and confirmed that 559 of the newly added medicines on the platform came from his company. Cuban framed cheaper drug access as a rare area of bipartisan consensus. 'Republicans want cheaper drugs, independents want cheaper drugs, Democrats want cheaper drugs and together, I think we're going to do something special,' Cuban said.

Health and Human Services Secretary Robert F. Kennedy Jr. called rising healthcare costs an 'existential threat' and credited Trump with pressuring pharmaceutical companies to lower prices. 'Almost 1 in 3 Americans, when they go to a drugstore, cannot afford to pick up the medications that their doctor prescribed for them,' Kennedy said. Centers for Medicare and Medicaid Services Administrator Mehmet Oz described TrumpRX.gov as 'the best transparency site ever created for medications.'

Trump's Most Favoured Nation Claim

Trump cited his administration's most favoured nation pricing agreements as the mechanism driving lower costs, claiming the US now pays 'the lowest price paid for anybody in any country' — a claim that goes beyond what independent analysts have verified. The administration has not released a detailed breakdown of which agreements are in force or how savings are being calculated. Notably, this is not the first time a US administration has floated most-favoured-nation drug pricing; earlier attempts under Trump's first term did not survive legal challenge.

What Comes Next

The expansion of TrumpRX.gov represents the most visible consumer-facing element of the administration's broader drug pricing push. Whether the platform's savings claims hold up to independent scrutiny — and whether pharmaceutical partners sustain their participation — will determine its long-term impact. Consumer advocacy groups and Congressional Democrats have yet to formally respond to the latest expansion.